Fig. 1: Resmetirom (MGL-3196), a liver-directed THR-β agonist, activates the THR-β receptor in the nucleus, driving the transcription of genes involved in lipid metabolism. | npj Gut and Liver

Fig. 1: Resmetirom (MGL-3196), a liver-directed THR-β agonist, activates the THR-β receptor in the nucleus, driving the transcription of genes involved in lipid metabolism.

From: Reviewing MAESTRO-NASH and the implications for hepatology and health systems in implementation/accessibility of Resmetirom

Fig. 1

This leads to enhanced β-oxidation of fatty acids, increased mitochondrial biogenesis, and mitophagy, while concurrently reducing de novo lipogenesis and promoting lipophagy. DIO1 Iodothyronine Deiodinase 1, OATP1B1 Organic anion transporting polypeptide 1B1, THR-β thyroid hormone receptor-β, T3 triiodothyronine, T4 tetraiodothyronine.

Back to article page